The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2017 | MURANO: safety and efficacy data presented at ASH 2017
Venetoclax is a Bcl-2 inhibitor approved in USA for CLL patients with 17p deletion, and in Europe for those who failed or do not tolerate BCR inhibitors. Here, Jennifer Brown, MD, PhD from Dana-Farber Cancer Institute, Boston, MA discusses the results presented at ASH 2017 on the MURANO trial, where venetoclax has been tested in combination with rituximab versus bendamustine plus rituximab. This video was recorded at the American Society of Hematology Annual Meeting 2017, held in Atlanta, GA.
